Halozyme Q3 net income rises 41% to $247.05 million

Bitget2026/11/05 21:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Halozyme Therapeutics’ third-quarter 2026 GAAP diluted earnings rose 41% year-over-year to $2.01 per share.
Total revenue climbed 39% to $492.97 million, while royalty revenue increased 44% to $341 million year-over-year.
A Dutch patent court granted an injunction blocking Merck’s Keytruda Qlex launch in eight European markets for infringing a Halozyme patent.
Full-year 2026 total revenue guidance increased to $1.86 billion–$1.93 billion, representing 33%–38% growth over 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90634) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Halozyme Q3 net income rises 41% to $247.05 million

You may also like

Crypto prices